...
首页> 外文期刊>European journal of ophthalmology >Retreatment of residual refractive errors with flap lift laser in situ keratomileusis.
【24h】

Retreatment of residual refractive errors with flap lift laser in situ keratomileusis.

机译:皮瓣提升激光原位角膜磨镶术治疗残余屈光不正。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To investigate the outcomes of flap lift laser-assisted in situ keratomileusis (LASIK) for residual refractive errors. METHODS: In this prospective study, 60 eyes of 48 patients (mean age 36 years; age range 23-53 years) underwent flap lift retreatment surgery following initial LASIK for the correction of residual refractive errors. All treatments were wavefront guided using the VISX S4 Star excimer laser. The main outcome measures were predictability, safety, efficacy, and stability. RESULTS: Following retreatment, epithelial ingrowth occurred in 23.3% (n=14) of eyes, which required a flap lift and scrape procedure in 4 eyes and a second flap lift and scrape procedure in 2 eyes. De novo dry eye occurred in 8.3% (n=5) of eyes. At 6 months, the mean (+/-SD) post-retreatment Snellen decimal uncorrected visual acuity (UCVA), sphere, cylinder, spherical equivalent (SE), defocus equivalent (DE), and best corrected visual acuity (BCVA) was 1.03+/-0.23, 0.08+/-0.34 diopters (D) (range -0.75 to +1.25 D), -0.53+/-0.37 D (range 0 to -1.75 D), -0.04+/-0.34 D (range -1.11 to +1.04 D), 0.29+/-0.41 D (range 0 to 1.94 D), and 1.13+/-0.15 (range 0.5 to 1.5), respectively. Seventy-three percent (n=44) of eyes had an UCVA equal to or greater than 1 (6/6), 88.3% (n=53) and 98.3% (n=59) of eyes were within +/-0.50 D and +/-1.00 D of SE, respectively, and 3.3% (n=2) of eyes lost 1 line of BCVA. CONCLUSIONS: A high incidence (23.3%, n=14) of epithelial ingrowth occurred following retreatment surgery and de novo dry eye occurred in 8.3% (n=5) of eyes. Despite this, reasonable visual and refractive outcomes were achieved at 6 months post-retreatment.
机译:目的:探讨皮瓣剥离激光辅助原位角膜磨镶术(LASIK)治疗残余屈光不正的结果。方法:在这项前瞻性研究中,对48例患者(平均年龄36岁;年龄范围23-53岁)中的60只眼在初始LASIK术后进行了皮瓣提升手术治疗,以矫正残余屈光不正。所有治疗均使用VISX S4 Star准分子激光在波前进行。主要结果指标是可预测性,安全性,疗效和稳定性。结果:再治疗后,在23.3%(n = 14)的眼中发生了上皮向内生长,这需要在4眼中进行皮瓣提起和刮擦,在第二眼中需要进行第二次皮瓣提起和刮擦。从头开始出现干眼症的比例为8.3%(n = 5)。在6个月时,Snellen十进制未矫正视力(UCVA),球体,圆柱体,球当量(SE),散焦当量(DE)和最佳矫正视力(BCVA)的平均(+/- SD)为1.03 +/- 0.23、0.08 +/- 0.34屈光度(D)(范围-0.75至+1.25 D),-0.53 +/- 0.37 D(范围0至-1.75 D),-0.04 +/- 0.34 D(范围- 1.11至+1.04 D),0.29 +/- 0.41 D(范围0至1.94 D)和1.13 +/- 0.15(范围0.5至1.5)。 73%(n = 44)的眼睛的UCVA等于或大于1(6/6),88.3%(n = 53)和98.3%(n = 59)的眼睛在+/- 0.50 D以内分别为SE的+/- 1.00 D和3.3%(n = 2)的眼睛失去了1行BCVA。结论:再治疗后上皮向内生长的发生率很高(23.3%,n = 14),而从头开始干眼的发生率为8.3%(n = 5)。尽管如此,复治后6个月仍达到了合理的视觉和屈光结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号